Negotiations between the state and the manufacturer of cystic fibrosis drug Orkambi have finally begun.
The news will be a relief to patients with cystic fibrosis and their families, who had begun to question why the health service had yet to decide whether it would seek to provide the drug – at a cost of €160,000 per patient per year.
The National Centre for Pharmacoeconomics (NCPE) recommended against funding the drug in June, but that...
Subscribe from just €1 for the first month!
Exclusive offers:
All Digital Access + eReader
Trial
€1
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
Annual
€200
€149 For the 1st Year
Unlimited Access for 1 Year
Team Pass
Get a Business Account for you and your team